Hospira, Inc.  

(Public, NYSE:HSP)   Watch this stock  
Find more results for William Bowles�
62.44
+2.19 (3.63%)
After Hours: 62.44 0.00 (0.00%)
Dec 18, 6:19PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 60.74 - 62.54
52 week 39.90 - 63.08
Open 61.21
Vol / Avg. 1.05M/1.13M
Mkt cap 10.26B
P/E 32.10
Div/yield     -
EPS 1.95
Shares 169.20M
Beta 0.55
Inst. own 93%
Feb 10, 2015
Q4 2014 Hospira Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 6, 2014
Q3 2014 Hospira Inc Earnings Release
Nov 6, 2014
Q3 2014 Hospira Inc Earnings Call - Webcast
Sep 30, 2014
Hospira at Deutsche Bank Leveraged Finance Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 13.51% -0.62%
Operating margin 19.77% -0.78%
EBITD margin - 10.59%
Return on average assets 9.67% -0.41%
Return on average equity 19.27% -0.28%
Employees 17,000 -
CDP Score - 50 E

Address

275 North Field Drive
LAKE FOREST, IL 60045
United States - Map
+1-847-9376472 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hospira, Inc. (Hospira) is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa (EMEA), and Asia Pacific (APAC). The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa, and the APAC segment includes Asia, Japan, Australia and New Zealand. In all segments, Hospira sells a line of products, including specialty injectable and other pharmaceuticals and medication management products. In July 2014, Hospira Inc acquired active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd.

Officers and directors

F. Michael Ball Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Thomas E. Werner Chief Financial Officer, Senior Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
David J. Endicott President, Hospira Medical Devices
Age: 49
Bio & Compensation  - Reuters
Kenneth F. Meyers Chief Human Resource Officer, Senior Vice President
Age: 52
Bio & Compensation  - Reuters
Daphne E. Jones Chief Information Officer, Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Sumant Ramachandra M.D., Ph.D. Senior Vice President, Chief Scientific Officer
Age: 45
Bio & Compensation  - Reuters
Richard John Davies Senior Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
John B. Elliot Senior Vice President - International Pharmaceutical Operations
Age: 62
Bio & Compensation  - Reuters
Zena G. Kaufman Senior Vice President - Quality
Age: 57
Bio & Compensation  - Reuters
Brian J. Smith Senior Vice President, Chief Legal Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance